Drug news
Exembol (Mitsubishi Tanabe) launched in UK for HIT
Mitsubishi Tanabe Pharma's (MTP) has launched the direct thrombin inhibitor Exembol (argatroban) in the UK for the treatment of adult patients with Heparin-Induced Thrombocytopenia type II (HIT) who require parenteral antithrombotic therapy. Exembol is already launched in Netherlands, Germany/Austria/Scandinava and is marketed in the US by GSK.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins